Pages that link to "Q36825077"
Jump to navigation
Jump to search
The following pages link to Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule (Q36825077):
Displaying 10 items.
- Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition (Q28475976) (← links)
- Advances in structure elucidation of small molecules using mass spectrometry (Q28743720) (← links)
- Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma (Q33440533) (← links)
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias (Q33952759) (← links)
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma (Q34114592) (← links)
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia (Q37142145) (← links)
- A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy (Q37168430) (← links)
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia (Q37602430) (← links)
- A phase I trial of flavopiridol in relapsed multiple myeloma (Q37624722) (← links)
- A novel liposomal formulation of flavopiridol (Q41900653) (← links)